A live biotherapeutic product (LBP) is developed as a biological drug to treat, prevent, or diagnose disease, so it demands drug-level evidence, controls, and alignment with FDA biologics regulations. A probiotic supplement is typically positioned as a food or dietary supplement to support normal function, with more limited claims and different evidence expectations. Below are the practical differences in definition, regulation, CMC, and how to choose the right pathway for microbiome therapeutics.
What is a live biotherapeutic product (LBP)?
A live biotherapeutic product (LBP) is a biological product that contains live microorganisms and is intended to prevent, treat, or diagnose a disease or condition in humans. Because the intended use is medical, an LBP is developed like a drug, not like a food ingredient.
Core characteristics typically expected for an LBP include clear strain identity (often down to strain-level designation), defined potency (for example, viable cell count at release and through shelf life), and a plausible mechanism of action that links microbial activity to a clinical endpoint. Development programmes also usually address patient population fit, safety monitoring, and how the product behaves in the gastrointestinal environment (survival, engraftment potential, and functional outputs).
What is a probiotic supplement?
A probiotic supplement is a product containing live microorganisms intended to support normal physiological function or maintain general wellbeing, rather than treat or prevent disease. It is commonly marketed as a dietary supplement or as part of a food format, depending on jurisdiction and presentation.
Probiotic supplements generally rely on structure or function style claims and labelling norms such as genus, species, strain (when available), and a stated viable count through the end of shelf life. The evidence package often focuses on safety, quality, and substantiation appropriate to the claim scope, rather than drug-style demonstration of efficacy against a disease endpoint.
How do regulation and evidence requirements differ between LBPs and probiotic supplements?
The main difference is the intended claim. LBPs follow drug or biologic pathways, while probiotic supplements follow food or dietary supplement pathways. That difference drives what you can claim, what evidence you need, and how regulators assess risk.
| Area | LBP (biologic drug) | Probiotic supplement (food/supplement) |
|---|---|---|
| Regulatory framing | Aligned with FDA biologics regulations and drug development expectations | Food or supplement rules, claim scope is narrower |
| Permitted claims | Treat, prevent, diagnose disease (if approved) | Support normal function, no disease treatment claims |
| Evidence expectations | Clinical efficacy and safety, plus mechanistic rationale | Substantiation proportionate to the claim, often less extensive |
| Manufacturing oversight | Drug-grade controls, strong traceability and change control | Food-grade controls, still requires robust quality systems |
For both categories, strain-specific evidence matters, but the depth, endpoints, and level of regulatory scrutiny are typically higher for LBPs because patient risk and medical claims are higher.
What are the key differences in development, manufacturing, and quality control?
LBPs generally require tighter control across development and CMC because the microorganism is the active substance. Probiotic supplements also need strong quality control, but the programme is usually built around consistency and substantiation for non-disease claims.
- Strain characterisation: confirmed identity, genetic stability, and clear strain traceability across banks and batches.
- Potency and viability testing: methods must be fit for purpose, reproducible, and linked to the labelled dose and shelf-life claims.
- Stability: sensitivity to oxygen, moisture, temperature, and excipients, plus packaging and cold-chain decisions.
- Delivery and performance: survival through upper GI conditions, release profile, and interaction with resident microbiota.
- Batch consistency: controls for fermentation conditions, downstream processing, and acceptable ranges for impurities and contaminants.
- Safety monitoring: more extensive for LBPs, including risk-based assessment of translocation, antimicrobial resistance considerations, and patient population vulnerabilities.
Across both pathways, weak viability or potency methods can create false negatives in R&D and major comparability issues later, especially when scaling or changing manufacturing sites.
How do you decide whether your product should be developed as an LBP or a probiotic supplement?
You decide based on your intended use and claim, then work backwards into evidence, timelines, and risk. If your product is positioned as a microbiome therapeutic for a defined disease endpoint, an LBP pathway is usually the logical fit. If it is positioned for general support of normal function, a probiotic supplement pathway is often more appropriate.
Decision checklist
- Claim: do you need treat or prevent disease language, or only structure or function support?
- Target population: patients under medical supervision, or general population use?
- Endpoints: clinical disease endpoints versus functional or biomarker substantiation.
- Risk profile: immunocompromised use, co-medications, and safety monitoring burden.
- Evidence plan: level of strain-specific evidence needed, including mechanism and dose-response.
- CMC readiness: ability to lock identity, potency, stability, and comparability early.
- Budget and timeline: drug development typically requires larger budgets and longer timelines, often in the € millions.
- Go-to-market: prescription or clinical channel versus retail and practitioner channels.
How Cryptobiotix helps with live biotherapeutic products vs probiotic supplements?
Cryptobiotix supports preclinical gut microbiome research for both LBP and probiotic supplement programmes by generating fast, mechanistic, strain-specific evidence to de-risk key R&D decisions before costly downstream steps.
- Use SIFR® technology to test microbiome responses ex vivo, supporting mechanism-of-action and dose selection questions.
- Build a stronger evidence package with structured outputs aligned to scientific evidence expectations for microbiome therapeutics and functional products.
- Apply fit-for-purpose study designs across sectors and formats via our applications focus, including human and animal health contexts.
- Accelerate decision-making on candidate ranking, responder variability, and formulation choices before committing to larger investments.
If you want to clarify whether your concept fits an LBP or probiotic supplement pathway, and what preclinical evidence will reduce risk, contact us via the contact page.
